Edwards Lifesciences Corporation $EW Stock Sold by Boston Trust Walden Corp

Key Points

• Boston Trust Walden cut its Edwards Lifesciences stake by 5.3% in the third quarter, selling 13,624 shares; it retained 243,598 shares valued at about $21 million.
• Institutional investors own 79.46% of the stock. Assenagon Asset Management increased its stake by 50% in the quarter, contrasting with Boston Trust Walden’s reduction.
• Edwards beat quarterly estimates, reporting EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion, up 10.5% year over year. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $108.88.

Boston Trust Walden Corp trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 243,598 shares of the medical research company's stock after selling 13,624 shares during the quarter. Boston Trust Walden Corp's holdings in Edwards Lifesciences were worth $21,027,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $5,318,092,000. Varma Mutual Pension Insurance Co bought a new position in shares of Edwards Lifesciences in the second quarter worth about $11,168,000. Conway Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $954,000. Commerce Bank bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $3,121,000. Finally, Assenagon Asset Management S.A. lifted its stake in Edwards Lifesciences by 50.0% in the third quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company's stock worth $234,727,000 after acquiring an additional 906,345 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on EW shares. Rothschild & Co Redburn raised their price objective on Edwards Lifesciences from $99.00 to $102.00 and gave the company a "buy" rating in a research report on Monday, July 27th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $105.00 to $120.00 and gave the company an "overweight" rating in a research note on Thursday. Truist Financial set a $113.00 price target on Edwards Lifesciences and gave the stock a "buy" rating in a research report on Wednesday. Citigroup increased their price objective on Edwards Lifesciences from $110.00 to $117.00 and gave the company a "buy" rating in a report on Thursday. Finally, Barclays raised their price objective on Edwards Lifesciences from $110.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday. Twenty-three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $108.88.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $100.70 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock has a market capitalization of $57.99 billion, a price-to-earnings ratio of 33.80, a PEG ratio of 2.60 and a beta of 0.85. The firm's 50 day simple moving average is $88.68 and its 200-day simple moving average is $85.69. Edwards Lifesciences Corporation has a 12 month low of $74.66 and a 12 month high of $104.17.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.06. The firm had revenue of $1.72 billion for the quarter, compared to analysts' expectations of $1.68 billion. Edwards Lifesciences had a return on equity of 16.25% and a net margin of 15.30%. The company's quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $0.67 EPS. Analysts expect that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the business's stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,045 shares of company stock worth $451,596 in the last quarter. Company insiders own 0.31% of the company's stock.

Trending Headlines about Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards beat Q3 estimates, reporting adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion, up about 11% year over year. It raised its full-year sales outlook and set adjusted EPS guidance of $2.97–$3.05. TAVR sales grew 8.8%, while transcatheter mitral and tricuspid therapies (TMTT) grew 45.6%, supporting the growth outlook. Q3 earnings and outlook
• Positive Sentiment: New PROGRESS Trial data found TAVR performed better than active surveillance for at-risk patients with moderate aortic stenosis, including fewer combined death or heart-failure events and better quality-of-life measures. The findings could support broader future use, though they do not by themselves establish a change in treatment or reimbursement. PROGRESS Trial data
• Positive Sentiment: Analysts responded favorably to the results: UBS raised its target to $118 and JPMorgan to $120, while other firms also increased targets and several upgraded the shares. The revisions signal improved expectations, but are analyst opinions rather than guaranteed returns. UBS price-target increase JPMorgan price-target increase
• Negative Sentiment: Edwards’ CEO acknowledged that more competition is coming in TAVR, a potential challenge to market share and growth. CEO comments on TAVR competition

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.